Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 5, Issue 10 (2016)

The Role of Tissue Inhibitor of Matrix Metalloproteinase-1 in Cardiac and Blood Vessels Remodeling and in Potential for Survival in Case of Chronic Heart Failure of Various Origins

Author(s):
RI Yatsyshyn and TI Salyzhyn
Abstract:
Results. Direct moderate reliable connection was established between TIMP-1 and end-diastolic volume (EDV) (r=+0.36; p<0.05), left ventricular mass index (LVMI) (r=+0.46; p<0.05), thickness of left ventricular posterior wall (r=+0.33; p<0.05), interventricular septum thickness (r=+0.39; p<0.05) in Group I (p<0.05), whereas the connection between TIMP-1 and end-systolic volume (ESV) (r=+0.36; p<0.05), EDV (r=+0.38; p<0.05), LVMI (r=+0.42; p<0.05), anteroposterior dimension of right ventricle (r=+0.43; p<0.05) was established in Group II. In order to assess the impact of TIMP-1 on ED we conducted correlation analysis between TIMP-1 and ET-1 between the studied parameters in both groups, in Group I (r=+0.73; р<0.001) and in Group II (r=+0.70; р<0.001). Increase in TIMP-1 level over 1040 ng/ml was associated with a greater risk of hospitalization for CHF decompensation and cardiovascular complications (CVC) development during 2 years in patients of both groups. Conclusions. The results of this research indicate that increased TIMP-1 level is an independent predictor of increase in hospitalization and mortality of patients with CHF regardless of renal function. Increase in TIMP-1 level may promote cardiac and blood vessels remodeling in patients with comorbidities. Increase in TIMP-1 level is associated with the development of endothelial dysfunction in both groups.
Pages: 85-91  |  1426 Views  113 Downloads


The Pharma Innovation Journal
How to cite this article:
RI Yatsyshyn, TI Salyzhyn. The Role of Tissue Inhibitor of Matrix Metalloproteinase-1 in Cardiac and Blood Vessels Remodeling and in Potential for Survival in Case of Chronic Heart Failure of Various Origins. Pharma Innovation 2016;5(10):85-91.

Call for book chapter